Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
900P - Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study
Presenter: Renata Ferrarotto
Session: Poster session 02
901P - A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma
Presenter: Sehhoon Park
Session: Poster session 02
902P - Comparison of progression free and overall survival (OS) with bicalutamide and 4-weekly or 12-weekly triptorelin in androgen receptor positive (AR+) salivary gland cancer (SGC)
Presenter: Amelia Handley
Session: Poster session 02
903P - Patterns and predictors of recurrence-free survival (RFS) in salivary gland cancers (SGCs): A Spanish multicenter study
Presenter: Alexandre Izquierdo Miranda
Session: Poster session 02
904P - Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
Presenter: Laura Spurgeon
Session: Poster session 02
905P - Validation of MYC/TP63 classification for adenocystic carcinomas of salivary glands
Presenter: Panagiota Economopoulou
Session: Poster session 02
906P - Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)
Presenter: Mario Balsa Pena
Session: Poster session 02